COA
- Product Details
- Data Display
- Reviews & Citations
- Resources
1/3
BFPP, BPPR, GPR56, TM7LN4, TM7XN1
Human GPR56 Full Length Protein-VLP (GP6-H52P7) is expressed from human 293 cells (HEK293). It contains AA Arg 26 - Ile 693 (Accession # Q9Y653-1).
Predicted N-terminus: Arg 26
*The isotype control of empty/mock VLP (Cat. No. VLP-N5213) is sold separately and not included in protein, you can follow the link for product information.
Virus-like particles (VLPs) are protein particles that mimic the shape of viruses but lack a viral genome, and incorporating transmembrane proteins on the external surface.
Envelope virus-like particles (eVLPs) are produced by co-expressing target membrane proteins with viral structural proteins in mammalian cells, enabling native embedding of membrane proteins into the lipid bilayer during VLP budding. This approach preserves authentic conformation, post-translational modifications, and orientation, while creating a completely detergent-free environment with repetitive multivalent display and strong immunogenicity making them ideal for immunization, binding assays in antibody discovery and screening (ELISA), and cell-based assays such as FACS, etc.
Less than 1.0 EU per μg by the LAL method / rFC method.
>95% as determined by SEC-HPLC.
The VLPs are highly immunogenic, so the immunization strategy should be optimized (antigen dose, regimen and adjuvant).
Supplied as 0.2 μm filtered solution in PBS, Arginine, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
This product is supplied and shipped on dry ice.
Please avoid repeated freeze-thaw cycles.